Hare
HomeInsights

INDUSTRY:

Pharma

TOPIC:

Products & Services, Business & People

TITLE:

EMA: First particular replacement remedy for treating rare bleeding disorder

BRIEF:

The European Medicines Agency (EMA) has recommended granting a marketing authorization for Coagadex (human coagulation factor X) to treat factor X deficiency, a rare inherited bleeding disorder. 

LEGAL IMPLICATIONS:

BUSINESS IMPLICATIONS:

Special Report

In an unexpected move, just before the end of 2011, ...

Case Study

Improving expenditure efficiency has been, for a ver...

Your Portal Link to Mass Media Universe.

Valuable Quarterly Romanian Market Analysis.

Ask the analyst

Tailor-made advice for you

Feature Company